MX2019012364A - Proteinas de union a antigenos trem2 y usos de estas. - Google Patents

Proteinas de union a antigenos trem2 y usos de estas.

Info

Publication number
MX2019012364A
MX2019012364A MX2019012364A MX2019012364A MX2019012364A MX 2019012364 A MX2019012364 A MX 2019012364A MX 2019012364 A MX2019012364 A MX 2019012364A MX 2019012364 A MX2019012364 A MX 2019012364A MX 2019012364 A MX2019012364 A MX 2019012364A
Authority
MX
Mexico
Prior art keywords
antigen binding
binding proteins
trem2
myeloid cells
antibodies
Prior art date
Application number
MX2019012364A
Other languages
English (en)
Inventor
Foltz Ian
SAMBASHIVAN Shilpa
Chen Irwin
Miki Harris Susie
Toledo Warshaviak Dora
DRIVER Ian
lu Daniel
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2019012364A publication Critical patent/MX2019012364A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente invención se refiere a proteínas de unión a antígenos, tales como anticuerpos monoclonales, que se unen específicamente y activan el receptor de activación humano expresado en células mieloides 2 (TREM2) y composiciones farmacéuticas que comprenden dichas proteínas de unión a antígenos. Las proteínas de unión a antígenos agonistas (por ejemplo, anticuerpos) de la invención son capaces de activar la señalización de TREM2/DAP12 en células mieloides en ausencia de reticulación mediada por Fc de las proteínas de unión a antígenos. También se describen métodos para tratar o prevenir afecciones asociadas a la pérdida de función de TREM2, tales como la enfermedad de Alzheimer y la esclerosis múltiple, mediante el uso de proteínas de unión a antígenos.
MX2019012364A 2017-04-21 2018-04-20 Proteinas de union a antigenos trem2 y usos de estas. MX2019012364A (es)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762488691P 2017-04-21 2017-04-21
US201762530753P 2017-07-10 2017-07-10
US201762580400P 2017-11-01 2017-11-01
PCT/US2018/028691 WO2018195506A1 (en) 2017-04-21 2018-04-20 Trem2 antigen binding proteins and uses thereof

Publications (1)

Publication Number Publication Date
MX2019012364A true MX2019012364A (es) 2019-11-28

Family

ID=63856168

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2019012364A MX2019012364A (es) 2017-04-21 2018-04-20 Proteinas de union a antigenos trem2 y usos de estas.

Country Status (20)

Country Link
US (2) US11186636B2 (es)
EP (1) EP3612218A4 (es)
JP (2) JP7252134B2 (es)
KR (1) KR20200018778A (es)
CN (1) CN110709100A (es)
AU (2) AU2018254600B2 (es)
BR (1) BR112019021991A2 (es)
CA (1) CA3060409A1 (es)
CL (1) CL2019003000A1 (es)
CO (1) CO2019012998A2 (es)
CR (2) CR20190525A (es)
JO (1) JOP20190248A1 (es)
MA (1) MA52273A (es)
MX (1) MX2019012364A (es)
PE (1) PE20200485A1 (es)
PH (1) PH12019502356A1 (es)
SG (1) SG11201909646TA (es)
TW (1) TWI812619B (es)
UY (1) UY37698A (es)
WO (1) WO2018195506A1 (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201913611QA (en) 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
TWI811229B (zh) * 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020121195A1 (en) * 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
MA54880A (fr) * 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
JP2022520868A (ja) 2019-02-20 2022-04-01 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CA3146777A1 (en) * 2019-08-02 2021-02-11 CTTQ-Akeso (ShangHai) Biomed. Tech. Co., Ltd. Anti-pd-1 antibody and pharmaceutical use thereof
TW202128771A (zh) * 2020-01-13 2021-08-01 美商戴納立製藥公司 抗trem2 抗體及其使用方法
CN115279790A (zh) 2020-01-13 2022-11-01 戴纳立制药公司 抗trem2抗体和其使用方法
CA3167851A1 (en) 2020-02-24 2021-09-02 Francesca CIGNARELLA Methods of use of anti-trem2 antibodies
CN115667308A (zh) 2020-04-03 2023-01-31 艾利妥 抗trem2抗体的使用方法
AU2021392813A1 (en) * 2020-12-04 2023-06-29 Vigil Neuroscience, Inc. Treatment of diseases related to atp-binding cassette transporter 1 dysfunction using trem2 agonists
WO2023047100A1 (en) * 2021-09-21 2023-03-30 Quell Therapeutics Ltd Anti-trem2 chimeric antigen receptor
TW202330614A (zh) * 2021-11-22 2023-08-01 美商維佳神經科學有限公司 抗ｔｒｅｍ２抗體及其用途
TW202340235A (zh) 2021-12-17 2023-10-16 美商戴納立製藥公司 多肽工程、文庫及工程ｃｄ９８重鏈以及轉鐵蛋白受體結合多肽
WO2023164516A1 (en) 2022-02-23 2023-08-31 Alector Llc Methods of use of anti-trem2 antibodies
WO2023192282A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Methods for treating brain glucose hypometabolism
WO2023192288A1 (en) 2022-03-28 2023-10-05 Denali Therapeutics Inc. Monovalent anti-trem2 binding molecules and methods of use thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024052343A1 (en) 2022-09-06 2024-03-14 Institut National de la Santé et de la Recherche Médicale Trem-2 agonists for the treatment of marfan syndrome
CN117964768A (zh) * 2024-04-02 2024-05-03 上海宏成药业有限公司 抗trem2抗体及其用途

Family Cites Families (180)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6878687B1 (en) 1997-03-07 2005-04-12 Human Genome Sciences, Inc. Protein HMAAD57
EP0972029A1 (en) 1997-03-07 2000-01-19 Human Genome Sciences, Inc. Human secreted proteins
EP1090118A2 (en) 1998-06-26 2001-04-11 Incyte Pharmaceuticals, Inc. Human signal peptide-containing proteins
AUPQ873300A0 (en) 2000-07-12 2000-08-03 Medvet Science Pty. Ltd. A binding motif of a receptor (2)
CN101289511A (zh) 2000-04-11 2008-10-22 杰南技术公司 多价抗体及其应用
EP1351702B1 (en) 2000-12-08 2015-03-04 Bioprovar Corporation Trem-1 splice variant for use in modifying immune responses
US8231878B2 (en) 2001-03-20 2012-07-31 Cosmo Research & Development S.P.A. Receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US8981061B2 (en) 2001-03-20 2015-03-17 Novo Nordisk A/S Receptor TREM (triggering receptor expressed on myeloid cells) and uses thereof
CA2342376C (en) 2001-03-20 2013-11-12 Marco Colonna A receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
US20030077282A1 (en) 2001-10-12 2003-04-24 Bigler Michael Eric Use of bispecific antibodies to regulate immune responses
WO2003080667A2 (en) 2002-03-22 2003-10-02 Bioxell S.P.A. A novel receptor trem (triggering receptor expressed on myeloid cells) and uses thereof
AU2003242396A1 (en) 2002-05-24 2003-12-12 Takeda Pharmaceutical Company Limited Insulin resistance improving agents
US20090010920A1 (en) 2003-03-03 2009-01-08 Xencor, Inc. Fc Variants Having Decreased Affinity for FcyRIIb
US9714282B2 (en) 2003-09-26 2017-07-25 Xencor, Inc. Optimized Fc variants and methods for their generation
GB0401730D0 (en) 2004-01-27 2004-03-03 Bioxell Spa Diagnosis method
ES2426725T3 (es) * 2004-05-27 2013-10-24 Crucell Holland B.V. Método para identificar moléculas de unión que pueden neutralizar el virus de la rabia
US7700099B2 (en) 2005-02-14 2010-04-20 Merck & Co., Inc. Non-immunostimulatory antibody and compositions containing the same
US8101345B1 (en) 2005-03-25 2012-01-24 Isis Pharmaceuticals, Inc. Proinflammatory nucleic acids
KR20060135280A (ko) 2005-06-24 2006-12-29 전남대학교산학협력단 선천성 면역에 관여하는 트렘-2의 클로닝
WO2007005879A2 (en) 2005-07-01 2007-01-11 The Johns Hopkins University Compositions and methods for the treatment or prevention of disorders relating to oxidative stress
US20070041905A1 (en) 2005-08-19 2007-02-22 Hoffman Rebecca S Method of treating depression using a TNF-alpha antibody
DE202006007499U1 (de) 2006-05-11 2007-01-11 Osaka University Verwendung einer Zusammensetzung, die Plexin-A1-DAP12-Interaktion inhibiert, zur Behandlung von Entzündungs-, Autoimmun- oder Knochenresorptionserkrankungen
KR101571027B1 (ko) 2006-06-12 2015-11-23 이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 효과기 기능을 갖는 단일쇄 다가 결합 단백질
CA2551163A1 (en) 2006-07-17 2008-01-17 Boehringer Ingelheim International Gmbh Methods for treating inflammatory, autoimmune or bone resorption diseases
US7553936B2 (en) 2006-12-04 2009-06-30 The United States of America as represented by Secretary Department of Health and Human Services Anti-TREM-like transcript-1 (TLT-1) antibodies and compositions
CA2675583A1 (en) 2007-01-16 2008-07-24 Wyeth Inflammation treatment, detection and monitoring via trem-1
GR1007327B (el) 2007-08-08 2011-06-27 Ευαγγελος Γιαμαρελλος-Μπουρμπουλης Ο διαλυτος υποδοχεας ενεργοποιησης των μυελοκυτταρων (strem-1) ως δεικτης αποτελεσματικοτητας της θεραπειας του πεπτικου ελκους
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
KR100960684B1 (ko) 2008-02-22 2010-05-31 전남대학교산학협력단 Ｇａ733-2 발현 억제제로서의 ｔｒｅｍ-2 유전자, 및 이를포함하는 형질전환 동물 및 이의 사용방법
WO2010045479A1 (en) 2008-10-15 2010-04-22 The Board Of Trustees Of The University Of Illinois Phospholipid micellar and liposomal compositions and uses thereof
CA2759978C (en) 2009-04-28 2020-06-02 Life & Brain Gmbh Method for obtaining human microglial precursor cells from pluripotent stem cells
WO2010132370A2 (en) 2009-05-11 2010-11-18 Government Of The U.S.A., As Represented By The Secretary, Department Of Health And Human Services Soluble tlt-1 for the treatment and diagnosis of sepsis
JP5918129B2 (ja) 2009-06-22 2016-05-18 メディミューン，エルエルシー 部位特異的共役のための操作されたＦｃ領域
WO2011047097A2 (en) 2009-10-13 2011-04-21 Sigalov Alexander B Inhibition of trem receptor signaling with peptide variants
CN102038698A (zh) 2009-10-14 2011-05-04 山东绿叶天然药物研究开发有限公司 莫诺苷的新用途
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
CN102127168A (zh) 2010-01-19 2011-07-20 中国人民解放军第二军医大学 一种髓样细胞表达激发受体-1的重组融合蛋白及其应用
KR20110086460A (ko) 2010-01-22 2011-07-28 한국교원대학교산학협력단 수용성 수용체 라이브러리 및 이를 이용한 사이토카인 발현 조절 유전자의 스크리닝 방법
US9255136B2 (en) 2010-04-08 2016-02-09 Institut National De La Sante Et De La Recherche Medicale (Inserm) Inhibiting peptides derived from TREM-like transcript 1 (TLT-1) and uses thereof
KR20130098161A (ko) 2010-04-30 2013-09-04 알렉시온 파마슈티칼스, 인코포레이티드 인간에서 감소된 면역원성을 갖는 항체
WO2012016333A1 (en) 2010-08-06 2012-02-09 University Health Network Biomarkers for malaria
US20130130354A1 (en) 2010-09-28 2013-05-23 CTI Salud S.A. Novel genes and uses thereof, expression profile of colon, gastric and pancreatic cancer
EP2654792A4 (en) 2010-12-22 2016-05-11 Abbvie Inc HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
WO2012088290A2 (en) 2010-12-22 2012-06-28 Abbott Laboratories Tri-variable domain binding proteins and uses thereof
US10689447B2 (en) 2011-02-04 2020-06-23 Genentech, Inc. Fc variants and methods for their production
AU2012229251A1 (en) 2011-03-11 2013-09-12 Amgen Inc. Method of correlated mutational analysis to improve therapeutic antibodies
KR20120112973A (ko) 2011-04-04 2012-10-12 전남대학교산학협력단 비만 또는 제 2형 당뇨의 예방 또는 치료용 조성물
US20130058947A1 (en) 2011-09-02 2013-03-07 Stem Centrx, Inc Novel Modulators and Methods of Use
WO2013055958A1 (en) 2011-10-11 2013-04-18 Genentech, Inc. Improved assembly of bispecific antibodies
KR20200040924A (ko) 2011-10-21 2020-04-20 스템제닉스 인코포레이티드 생물학적 활성 분자의 세포내 전달을 위한 작용화 나노입자
JP6326371B2 (ja) 2011-11-04 2018-05-16 ザイムワークス，インコーポレイテッド Ｆｃドメインにおける変異を有する安定なヘテロ二量体抗体デザイン
EP2776061B1 (en) 2011-11-07 2019-08-14 MedImmune, LLC Multispecific and multivalent binding proteins and uses thereof
CA2859755C (en) 2011-12-23 2021-04-20 Pfizer Inc. Engineered antibody constant regions for site-specific conjugation and methods and uses therefor
CN102517287B (zh) 2012-01-10 2013-09-11 广西大学 抑制水牛TREM1基因表达的shRNA、慢病毒表达载体及其构建方法和应用
KR20130114951A (ko) 2012-04-10 2013-10-21 한양대학교 산학협력단 폴리감마글루탐산을 포함하는 Ｔｈ17 매개성 질환 예방 또는 치료용 조성물
JP6307080B2 (ja) 2012-09-07 2018-04-04 インセルム（インスティチュート ナショナル デ ラ サンテ エ デ ラ リシェルシェ メディカル） 骨髄細胞に発現する誘発性受容体１（ｔｒｅｍ−１）ｔｒｅｍ様転写産物１（ｔｌｔ−１）に由来する阻害ペプチドおよびその使用
KR101947702B1 (ko) 2012-10-04 2019-02-14 다나-파버 캔서 인스티튜트 인크. 인간 단클론 항-pd-l1 항체 및 사용 방법
WO2014065945A1 (en) 2012-10-23 2014-05-01 The Board Of Regents Of The University Of Texas System Antibodies with engineered igg fc domains
WO2014074942A1 (en) 2012-11-08 2014-05-15 Illumina, Inc. Risk variants of alzheimer's disease
US9066928B1 (en) 2012-12-04 2015-06-30 University Of Kentucky Research Foundation Method, composition, and kit useful for treatment of alzheimer's disease
US9580486B2 (en) 2013-03-14 2017-02-28 Amgen Inc. Interleukin-2 muteins for the expansion of T-regulatory cells
KR20150010326A (ko) 2013-07-19 2015-01-28 전남대학교산학협력단 비만 및 제 2형 당뇨 또는 지방간의 예방 또는 치료용 바이아릴아마이드를 포함한 유도체 화합물
CA2825821A1 (en) 2013-08-28 2015-02-28 Chiesi Farmaceutici S.P.A. 1-phenylalkanecarboxylic acid derivatives for the treatment of alzheimer's disease and multiple sclerosis
KR101402921B1 (ko) 2013-08-28 2014-06-02 전남대학교산학협력단 비만 또는 제 2형 당뇨의 치료를 위한 레스베라톨 유도체의 이용
WO2015037000A1 (en) 2013-09-11 2015-03-19 Compugen Ltd Vstm5 polypeptides and uses thereof as a drug for treatment of cancer, infectious diseases and immune related diseases
CN103555829B (zh) 2013-10-12 2015-10-21 厦门人瑞生物医药科技有限公司 一种检测trem2基因r47h突变的探针、试剂盒和方法
EP3092494A4 (en) 2014-01-06 2017-10-18 Children's Medical Center Corporation Biomarkers for dementia and dementia related neurological disorders
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CN103866041A (zh) 2014-04-04 2014-06-18 厦门大学 帕金森病和脑白质疏松症的突变检测试剂盒及其检测方法
CA2944784A1 (en) 2014-04-11 2015-10-15 Medimmune, Llc Conjugated compounds comprising cysteine-engineered antibodies
CN105218669A (zh) 2014-06-10 2016-01-06 河北翰林生物科技有限公司 制备抗人r47h-trem2突变体的人单克隆抗体的方法
US20170218091A1 (en) 2014-07-03 2017-08-03 Abbvie Inc. Monovalent binding proteins
LT3172232T (lt) 2014-07-17 2024-02-12 Novo Nordisk A/S Į vietą nukreipta trem-1 antikūnų mutagenezė, skirta klampumui sumažinti
SG10201913611QA (en) * 2014-08-08 2020-03-30 Alector Llc Anti-trem2 antibodies and methods of use thereof
KR101756417B1 (ko) 2014-08-21 2017-07-10 한국유나이티드제약 주식회사 금제제를 포함하는 간 섬유화 또는 간 경화의 예방 또는 치료용 약학적 조성물
IL283834B (en) 2014-09-28 2022-07-01 Univ California Modulation of stimulatory and non-stimulatory myeloid cells
US20170334977A1 (en) 2014-10-20 2017-11-23 The Brigham And Women's Hospital, Inc. Targeting Apolipoprotein E (APOE) in Neurologic Disease
US10081792B2 (en) 2014-12-31 2018-09-25 Wisconsin Alumni Research Foundation Derivation of human microglia from pluripotent stem cells
WO2016168771A2 (en) 2015-04-17 2016-10-20 Alpine Immune Sciences, Inc. Immunomodulatory proteins with tunable affinities
CA2986431C (en) 2015-05-18 2020-04-14 Synaptec Development Llc Galantamine clearance of amyloid.beta.
EP3307771A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
EP3307779A2 (en) 2015-06-12 2018-04-18 Alector LLC Anti-cd33 antibodies and methods of use thereof
US10765679B2 (en) 2015-07-04 2020-09-08 Emory University Use of TREM-1 inhibitors for treatment, elimination and eradication of HIV-1 infection
WO2017011342A1 (en) 2015-07-10 2017-01-19 Abbvie Inc. Igm-or-ige-modified binding proteins and uses thereof
HUE056201T2 (hu) 2015-07-30 2022-02-28 Macrogenics Inc PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
CN115960235A (zh) 2015-08-28 2023-04-14 艾利妥 抗siglec-7抗体及其使用方法
WO2017058866A1 (en) 2015-09-28 2017-04-06 Precision Immune, Inc. Anti-trem2 antibodies and uses thereof
SG10201912150TA (en) 2015-10-06 2020-02-27 Alector Llc Anti-trem2 antibodies and methods of use thereof
JP7060502B2 (ja) 2015-10-29 2022-04-26 アレクトル エルエルシー 抗Ｓｉｇｌｅｃ－９抗体及びその使用方法
US20170218058A1 (en) 2016-01-28 2017-08-03 Alector, LLC Anti-apoe4 antigen-binding proteins and methods of use thereof
WO2017139638A1 (en) 2016-02-11 2017-08-17 The Johns Hopkins University Compositions and methods for neuralgenesis
US11066456B2 (en) 2016-02-25 2021-07-20 Washington University Compositions comprising TREM2 and methods of use thereof
WO2017152102A2 (en) 2016-03-04 2017-09-08 Alector Llc Anti-trem1 antibodies and methods of use thereof
US10875919B2 (en) 2016-04-26 2020-12-29 Alector Llc Chimeric receptors and methods of use thereof
EP3452101A2 (en) 2016-05-04 2019-03-13 CureVac AG Rna encoding a therapeutic protein
US11944665B2 (en) 2016-06-01 2024-04-02 University Of Virginia Patent Foundation Methods and compositions for modulating lymphatic vessels in the central nervous system
WO2018015573A2 (en) 2016-07-22 2018-01-25 Deutsches Zentrum Für Neurodegenerative Erkrankungen E.V. (Dzne) Trem2 cleavage modulators and uses thereof
CN106244682B (zh) 2016-07-29 2019-11-26 中山大学 Trem-2基因在鉴别猪对蓝耳病毒易感性中的应用
CN106636330B (zh) 2016-09-21 2017-12-15 郁金泰 阿尔茨海默病的诊断和治疗药物
WO2018071898A1 (en) 2016-10-14 2018-04-19 Children's Medical Center Corporation Compositions and methods for treating diseases and disorders of the central nervous system
CN118027200A (zh) 2016-12-09 2024-05-14 艾利妥 抗SIRPα抗体及其使用方法
US20200095280A1 (en) 2016-12-23 2020-03-26 Genervon Biopharmaceuticals Llc Methods of using GM6 in diagnosing and treating Alzheimers disease
US20190343882A1 (en) 2017-01-12 2019-11-14 Duke University Compositions and Methods for the Treatment of Demyelinating Conditions
WO2018134815A2 (en) 2017-01-17 2018-07-26 Yeda Research And Development Co. Ltd. Methods of treating neurodegenerative diseases by inducing disease-associated microglia (dam) cells
WO2018136598A1 (en) 2017-01-18 2018-07-26 Evelo Biosciences, Inc. Methods of treating cancer
WO2018140831A2 (en) 2017-01-27 2018-08-02 Silverback Therapeutics, Inc. Tumor targeting conjugates and methods of use thereof
US10143187B2 (en) 2017-02-17 2018-12-04 Denali Therapeutics Inc. Transferrin receptor transgenic models
US20210293794A1 (en) 2017-02-24 2021-09-23 University Of Hawii Cancer Center Metabolic biomarkers for the identification and characterization of alzheimers disease
JP2020513794A (ja) 2017-02-28 2020-05-21 ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア 多能性幹細胞および造血始原細胞からのヒトミクログリア様細胞の分化と使用
EP3599842A4 (en) 2017-03-21 2020-12-30 The Jackson Laboratory GENETICALLY MODIFIED MOUSE EXPRESSING HUMAN APOE4 AND TREM.P.R47H AND ASSOCIATED PROCEDURES FOR USE
KR101936249B1 (ko) 2017-04-04 2019-01-08 경희대학교 산학협력단 쿠마타케닌을 포함하는 암의 예방, 개선 또는 치료용 조성물
JOP20190248A1 (ar) 2017-04-21 2019-10-20 Amgen Inc بروتينات ربط مولد ضد trem2 واستخداماته
US20180318379A1 (en) 2017-05-01 2018-11-08 The Board Of Trustees Of The Leland Stanford Junior University Inhibition of triggering receptor expressed on myeloid cells 1 (trem1) to treat central nervous system disorders
US11359014B2 (en) 2017-05-16 2022-06-14 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
WO2018218090A1 (en) 2017-05-24 2018-11-29 Nanosomix, Inc. Detection of biomarkers on vesicles for the diagnosis and prognosis of diseases and disorders
CA3065171A1 (en) 2017-06-05 2018-12-13 Janssen Biotech, Inc. Engineered multispecific antibodies and other multimeric proteins with asymmetrical ch2-ch3 region mutations
US11649286B2 (en) 2017-06-25 2023-05-16 Systimmune Inc. Tri-specific antibodies
CN109206503A (zh) 2017-07-07 2019-01-15 厦门大学 一种蛋白用于制备防治阿尔茨海默病药物的用途
US20190008812A1 (en) 2017-07-07 2019-01-10 Washington University Methods for treating microglial dysfunction
WO2019016784A1 (en) 2017-07-21 2019-01-24 Universidade De Coimbra ANTI-NUCLEOLIN ANTIBODIES
KR20200032722A (ko) 2017-07-27 2020-03-26 노파르티스 아게 부분절단효소 내성 trem2 변이체
TWI811229B (zh) 2017-08-03 2023-08-11 美商阿列克特有限責任公司 抗trem2抗體及其使用方法
JP7299160B2 (ja) 2017-08-03 2023-06-27 アレクトル エルエルシー 抗ｃｄ３３抗体及びその使用方法
JP7267280B2 (ja) 2017-08-08 2023-05-01 パイオニア イミュノセラピューティクス インコーポレイテッド Ｔｒｅｍ１を発現する骨髄細胞を無能化させるための組成物および方法
CN111448212A (zh) 2017-09-14 2020-07-24 戴纳立制药公司 抗trem2抗体及其使用方法
WO2019068072A1 (en) 2017-09-29 2019-04-04 The General Hospital Corporation METHODS OF IDENTIFICATION AND TREATMENT OF ADRENOMYELONEUROPATHY (AMN)
US11364303B2 (en) 2017-09-29 2022-06-21 Pfizer Inc. Cysteine engineered antibody drug conjugates
JP7361037B2 (ja) 2017-10-03 2023-10-13 プリベイル セラピューティクス，インコーポレーテッド ライソゾーム病の遺伝子治療
WO2019079529A1 (en) 2017-10-17 2019-04-25 The Translational Genomics Research Institute TREM2 AGONISTS FOR STIMULATING MICROGLIA AND IDENTIFICATION METHODS
US10597462B1 (en) 2017-11-08 2020-03-24 University Of Puerto Rico Anti-TLT-1 antibody and uses thereof
EP3710015B1 (en) 2017-11-15 2024-01-17 Université Laval Use of srsf3 agents for the treatment and/or prevention of neurological conditions, cancer, bacterial infections or viral infections
CN109837330A (zh) 2017-11-28 2019-06-04 上海中优精准医疗科技股份有限公司 一种检测trem2基因多态性的探针及方法
AU2018383709A1 (en) 2017-12-12 2020-07-16 Pionyr Immunotherapeutics, Inc. Anti-TREM2 antibodies and related methods
US11470827B2 (en) 2017-12-12 2022-10-18 Alector Llc Transgenic mice expressing human TREM proteins and methods of use thereof
JP7268038B2 (ja) 2018-01-31 2023-05-02 アレクトル エルエルシー 抗ｍｓ４ａ４ａ抗体及びその使用方法
CA3091047A1 (en) 2018-02-14 2019-08-22 Yale University Compositions for modulation of a trem or treml protein and methods of use
NL2020520B1 (en) 2018-03-02 2019-09-12 Labo Bio Medical Invest B V Multispecific binding molecules for the prevention, treatment and diagnosis of neurodegenerative disorders
EP3768261A1 (en) 2018-03-22 2021-01-27 NSC THERAPEUTICS GmbH Compounds and methods for use in the treatment of microglia-mediated disorders
JP2021519594A (ja) 2018-04-02 2021-08-12 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 抗ｔｒｅｍ−１抗体およびその使用
CA3096545A1 (en) 2018-04-09 2019-10-17 The General Hospital Corporation Combination therapies for the treatment of amyotropic lateral sclerosis and related disorders
MX2020011828A (es) 2018-05-25 2021-02-09 Alector Llc Anticuerpos anti proteina alfa reguladora de se?ales (sirpa) y metodos de uso de los mismos.
CN112512638A (zh) 2018-06-08 2021-03-16 艾利妥 抗siglec-7抗体及其使用方法
CN108752482B (zh) 2018-06-12 2019-04-30 南京卡提医学科技有限公司 携带截短或未截短的髓样细胞触发性受体信号结构的嵌合抗原受体及其应用
US20210195879A1 (en) 2018-06-21 2021-07-01 The Jackson Laboratory Genetically modified mouse models of alzheimer's disease
CA3099176A1 (en) 2018-06-29 2020-01-02 Alector Llc Anti-sirp-beta1 antibodies and methods of use thereof
CA3106038A1 (en) 2018-07-12 2020-01-16 Corvus Pharmaceuticals, Inc. Methods for detecting and treating cancers having adenosine pathway activation
US11278575B2 (en) 2018-07-12 2022-03-22 Duke University Compositions and methods for the treatment of demyelinating conditions
US20210311076A1 (en) 2018-07-16 2021-10-07 University Of Virginia Patent Foundation Compositions and methods of diagnosis and treatment for neurological diseases
CN109112214A (zh) 2018-07-27 2019-01-01 复旦大学附属中山医院 模式识别受体trem2在肝癌预后和治疗中的应用
WO2020023920A1 (en) 2018-07-27 2020-01-30 Alector Llc Anti-siglec-5 antibodies and methods of use thereof
TW202016307A (zh) 2018-08-31 2020-05-01 美商阿列克特有限責任公司 抗cd33 抗體及其使用方法
WO2020051322A1 (en) 2018-09-05 2020-03-12 The General Hospital Corporation Methods of treating cytokine release syndrome
AU2019339452A1 (en) 2018-09-11 2021-03-25 Washington University Anti-trem-2 agonist antibodies
WO2020056114A1 (en) 2018-09-12 2020-03-19 Board Of Regents Of The University Of Nebraska Antimicrobial compositions and methods
BR112021005808A2 (pt) 2018-09-28 2021-07-27 Inotrem uso de níveis de trem-1 solúveis para identificar indivíduos suscetíveis a responder a uma terapia anti-inflamatória
UY38407A (es) 2018-10-15 2020-05-29 Novartis Ag Anticuerpos estabilizadores de trem2
KR102096282B1 (ko) 2018-10-15 2020-04-02 재단법인대구경북과학기술원 재조합 베큘로바이러스를 이용한 인간 ｔｒｅｍ２ 세포막 단백질의 효율적인 정제방법
KR102156165B1 (ko) 2018-10-29 2020-09-15 재단법인대구경북과학기술원 인간 ｔｒｅｍ２ 세포막 단백질에 대한 단일클론항체, 이를 생산하는 하이브리도마 세포주 및 이의 용도
CN111135185A (zh) 2018-11-02 2020-05-12 杭州星鳌生物科技有限公司 天然免疫激活通过调控髓系细胞触发受体trem2抑制大脑神经慢性炎症
WO2020097395A1 (en) 2018-11-08 2020-05-14 The Regents Of The University Of California Systems and methods for targeting cancer cells
WO2020112889A2 (en) 2018-11-26 2020-06-04 Denali Therapeutics Inc. Methods for treating dysregulated lipid metabolism
WO2020121195A1 (en) 2018-12-10 2020-06-18 Mor Research Applications Trem2 antibodies and uses thereof
TW202035442A (zh) 2018-12-20 2020-10-01 美商建南德克公司 經修飾之抗體Fc及其使用方法
CN109646668B (zh) 2019-01-04 2019-10-18 厦门大学 一种多肽用于制备防治阿尔茨海默病药物的用途
EP3906055A4 (en) 2019-01-04 2023-01-04 Trio Pharmaceuticals, Inc. MULTISPECIFIC PROTEIN MOLECULES AND THEIR USES
WO2020150214A1 (en) 2019-01-14 2020-07-23 University Of Virginia Patent Foundation Use of integrin inhibitors for treatment or prevention of a neurological immunity disorder and/or nervous system injury
US20220104468A1 (en) 2019-01-22 2022-04-07 St. Jude Children's Research Hospital Modulation of lc3-associated endocytosis pathway and genetically modified non-human animals as a model of neuroinflammation and neurodegeneration
WO2020154348A1 (en) 2019-01-23 2020-07-30 The Regents Of The University Of California Human genomic construct reporter cells and mouse models to screen therapeutics against microglia-expressed disease associated genes
WO2020160441A1 (en) 2019-02-01 2020-08-06 Avrobio, Inc. Compositions and methods for treating neurocognitive disorders
JP2022519829A (ja) 2019-02-01 2022-03-25 シアトル チルドレンズ ホスピタル （ディービーエイ シアトル チルドレンズ リサーチ インスティテュート） 組換え遺伝子発現を調節するための微小環境センサー
MA54880A (fr) 2019-02-01 2021-12-08 Avrobio Inc Compositions et procédés de traitement de troubles neurocognitifs
JP2022520868A (ja) 2019-02-20 2022-04-01 デナリ セラピューティクス インコーポレイテッド 抗ｔｒｅｍ２抗体及びその使用方法
WO2020194317A1 (en) 2019-03-28 2020-10-01 Yeda Research And Development Co. Ltd. Method of treating lipid-related disorders
CN110320368A (zh) 2019-05-30 2019-10-11 广州医科大学附属第一医院（广州呼吸中心） 基于trem2的诊断试剂盒及其在帕金森病诊断产品上的应用
CN110241208A (zh) 2019-08-02 2019-09-17 辽宁中医药大学 Trem2作为早期诊断冠心病的分子标志物的应用
CN110511240B (zh) 2019-08-27 2022-03-08 南京医科大学 一种髓细胞触发受体2的内源性配体及其应用
CN110882262A (zh) 2019-11-06 2020-03-17 南京医科大学 一种髓细胞触发受体2的激活用药及其应用
CA3159055A1 (en) 2019-11-22 2021-05-27 Forest Hoyt ANDREWS Trem2 antibodies and uses thereof
MX2022006073A (es) 2019-12-05 2022-08-04 Alector Llc Metodos para utilizar anticuerpos anti-trem2.
CN111184742B (zh) 2020-02-13 2022-06-24 中山大学附属第五医院 Trem-2+t细胞在制备用于治疗结核病药物中的应用

Also Published As

Publication number Publication date
AU2018254600B2 (en) 2022-05-26
CL2019003000A1 (es) 2020-02-14
PH12019502356A1 (en) 2020-12-07
JOP20190248A1 (ar) 2019-10-20
MA52273A (fr) 2021-04-28
TWI812619B (zh) 2023-08-21
CR20210171A (es) 2021-05-21
US11186636B2 (en) 2021-11-30
UY37698A (es) 2018-10-31
US20210054069A1 (en) 2021-02-25
AU2022221560A1 (en) 2022-09-22
CA3060409A1 (en) 2018-10-25
EP3612218A1 (en) 2020-02-26
JP2022188272A (ja) 2022-12-20
CR20190525A (es) 2020-03-20
PE20200485A1 (es) 2020-03-03
CO2019012998A2 (es) 2020-02-18
CN110709100A (zh) 2020-01-17
SG11201909646TA (en) 2019-11-28
WO2018195506A1 (en) 2018-10-25
KR20200018778A (ko) 2020-02-20
AU2018254600A1 (en) 2019-10-24
JP2020517249A (ja) 2020-06-18
EP3612218A4 (en) 2021-07-28
JP7252134B2 (ja) 2023-04-04
TW201906628A (zh) 2019-02-16
BR112019021991A2 (pt) 2020-06-16
US20220204611A1 (en) 2022-06-30

Similar Documents

Publication Publication Date Title
PH12019502356A1 (en) Trem2 antigen binding proteins and uses thereof
PH12017502358A1 (en) Factor xi antibodies and methods of use
WO2018017864A3 (en) Pvrig-binding agents and uses thereof
PH12018501882A1 (en) Binding proteins and methods of use thereof
GEP20237480B (en) Antibodies against signal-regulatory protein alpha and methods of use
IL270743A (en) Monoclonal antibodies to lymphocyte-associated protein - Tcytotoxic 4 (CTLA-4), preparations containing them and their uses
WO2017184619A3 (en) Agonistic antibodies that bind human cd40 and uses thereof
PH12021550764A1 (en) Trem2 stabilizing antibodies
MX2009012950A (es) ANTICUERPOS HUMANIZADOS CONTRA EL GLOBULOMERO Aß (20-42) Y SUS USOS.
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
MX2022007288A (es) Agentes de union a ilt3 y metodos de uso de los mismos.
WO2020121195A8 (en) Trem2 antibodies and uses thereof
WO2020136145A3 (en) Leucocyte immunoglobulin-like receptor 2 neutralizing antibodies
JOP20210326A1 (ar) أجسام مضادة للمستقبل 1 لببتيد إدرار الصوديوم في البول وطرق استخدامها
PH12020500664A1 (en) C3-binding agents and methods of use thereof
MX2019009498A (es) Anticuerpos mimeticos de fgf21 y usos de los mismos.
MX2021006362A (es) Anticuerpos de dominio simple contra cll-1.
MX2020009522A (es) Anticuerpos anti-folato del receptor 1 y usos de los mismos.
WO2019094533A8 (en) Angptl8-binding agents and methods of use thereof
PH12020551805A1 (en) Cannabinoid receptor type 1 (cb1) binding proteins and uses thereof
EA202090791A1 (ru) Агонистические антитела против cd40
MX2020005364A (es) Anticuerpos anti-ox40 y usos de los mismos.
MX2021000688A (es) Anticuerpos anti-cd40 y usos de los mismos.
EP3854875A4 (en) HUMAN MONOCLONAL ANTIBODY BINDING SPECIFICALLY TO HUMAN HMGB1, AND PHARMACEUTICAL COMPOSITION FOR THE TREATMENT OR PREVENTION OF ALZHEIMER'S DISEASE CONTAINING SUCH HUMAN MONOCLONAL ANTIBODY
MX2022001882A (es) Proteinas de union a 4-1bb y ox40 y composiciones y metodos relacionados anticuerpos contra 4-1bb, anticuerpos contra ox40.